CNTB — CONNECT BIOPHARMA HLDGS LTD
Public company
InvestorLens aggregates public filing data to show which tracked investors reported holdings in this stock. Dollar values represent reported position values, not market capitalization, and may be delayed up to 45 days. Not a recommendation.
Sourced from SEC EDGAR public filings
About CONNECT BIOPHARMA HLDGS LTD (CNTB)
CONNECT BIOPHARMA HLDGS LTD (CNTB) appears in the most recent 13F filings of 3 tracked institutional investors. The largest disclosed position is held by Izzy Englander (Millennium Management), valued at $1M. Across recent filings, tracked investors recorded 2 new positions, 0 increased, 0 reduced, and 0 exited. All data sourced from SEC 13F filings.
Based on recent institutional activity in CNTB
How many top investors track CNTB
A small number of top investors own this.
CNTB Ownership Composition
How CONNECT BIOPHARMA HLDGS LTD is held across tracked investor types, based on reported 13F positions.
- Other96.7%
- Hedge Funds3.3%
Tracked investors reporting CNTB
- Izzy EnglanderMar 31, 2026Millennium ManagementShares474.6KValue$1.2M% Portfolio0.00%
- Ken GriffinMar 31, 2026Citadel AdvisorsShares112.7KValue$295.2K% Portfolio0.00%
- Steve CohenMar 31, 2026Point72 Asset ManagementShares19.8KValue$51.8K% Portfolio0.00%
Recent activity
- New$46.5KFeb 17, 2026
- New$51.8KMay 15, 2026
Frequently asked questions
- How many institutional investors hold CNTB?
- 3 tracked institutional investors disclosed a position in CNTB (CONNECT BIOPHARMA HLDGS LTD) in their most recent 13F filing.
- Who is the largest institutional holder of CNTB?
- Izzy Englander, Millennium Management, holds the largest disclosed position in CNTB, valued at $1M.
- Did institutional ownership of CNTB increase or decrease?
- Across recent 13F filings, tracked investors recorded 2 new positions, 0 increased, 0 reduced, and 0 fully exited CNTB.
- Where does this CNTB ownership data come from?
- SEC Form 13F-HR filings, accessed via EDGAR. 13F filings are disclosed quarterly with a 45-day reporting delay and cover U.S.-listed long equity positions only. This is not investment advice.